Loading stock data…
VKTX
$30.00-1.18 (-3.78%)
Market ClosedLast close May 1
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Viking Therapeutics, Inc. in the Healthcare sector is trading at $30.00. The stock is currently 30% below its 52-week high of $43.15, remaining 8.4% below its 200-day moving average. Technical signals show oversold RSI of 19 and bearish MACD signal, explaining why VKTX maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 19) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$30.00
Potential Upside
5%
Whystock Fair Value$31.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus18 analysts
Mean target$92.44+208.1%
Range$34.00 – $125.00
Fundamentals
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.84%
Volume
Today's trading volume
2.84M
Recent News
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs
Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.
Viking Therapeutics Inc (VKTX) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid ...
Viking Therapeutics Inc (VKTX) reports increased R&D expenses and net loss, while making significant progress in clinical trials and maintaining a strong cash position.
Viking Therapeutics Q1 Earnings Call Highlights
Viking Therapeutics (NASDAQ:VKTX) reported first-quarter 2026 financial results and outlined progress across its obesity pipeline during an earnings call held April 29, 2026. Management emphasized rapid advancement of its dual GLP-1/GIP agonist VK2735 in both injectable and oral formulations, expans
What is Driving a Strong Bullish Sentiment Towards Viking Therapeutics (VKTX)
Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 best biotech stocks with highest upside potential. Back on March 26, Viking Therapeutics Inc. (NASDAQ:VKTX) reported the final recruitment of patients into the Phase 3 VANQUISH-2 study of its investigational subcutaneous drug VK2735, a dual agonist of the GLP-1 and GIP receptors. The drug is being […]
Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?
Is VKTX a good stock to buy? We came across a bullish thesis on Viking Therapeutics, Inc. on Charlie Evans’s Substack by Charlie Evans PhD. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $35.53 as of April 20th. Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies […]